1-(3,4-bis(benzyloxy)benzyl)piperazine | 1345843-96-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-bis(benzyloxy)benzyl)piperazine
• 英文别名: 1-(3,4-Bis(benzyloxy)benzyl)piperazine；1-[[3,4-bis(phenylmethoxy)phenyl]methyl]piperazine
• CAS: 1345843-96-0
• 化学式: C₂₅H₂₈N₂O₂
• 分子量: 388.51
• InChiKey: ARQWLHMXRRSEEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3,4-bis(benzyloxy)benzyl)piperazine 在 碳酸氢钠 、 肼 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 2-(4-(3,4-bis(benzyloxy)benzyl)piperazin-1-yl)acetohydrazide
  参考文献：
  名称：

  Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)

  摘要：

  Procaspase-Activating Compound 1 (PAC-1) is an ortho-hydroxy N-acyl hydrazone that enhances the enzymatic activity of procaspase-3 in vitro and induces apoptosis in cancer cells. An analogue of PAC-1, called S-PAC-1, was evaluated in a veterinary clinical trial in pet dogs with lymphoma and found to have considerable potential as an anticancer agent. With the goal of identifying more potent compounds in this promising class of experimental therapeutics, a combinatorial library based on PAC-1 was created, and the compounds were evaluated for their ability to induce death of cancer cells in culture. For library construction, 31 hydrazides were condensed in parallel with 27 aldehydes to create 837 PAC-1 analogues, with an average purity of 91%. The compounds were evaluated for their ability to induce apoptosis in cancer cells, and through this work, six compounds were discovered to be substantially more potent than PAC-1 and S-PAC-1. These six hits were further evaluated for their ability to relieve zinc-mediated inhibition of procaspase-3 in vitro. In general, the newly identified hit compounds are two- to four-fold more potent than PAC-1 and S-PAC-1 in cell culture, and thus have promise as experimental therapeutics for treatment of the many cancers that have elevated expression levels of procaspase-3.

  DOI：

  10.1021/co2001372
• 作为产物：
  描述：

  3,4-二苄氧基氯 、 哌嗪 在 silica gel 、 乙酸乙酯 、 甲醇 作用下， 以 四氢呋喃 为溶剂， 以afforded 5{10} (2.12 g, 92%) as a beige solid的产率得到1-(3,4-bis(benzyloxy)benzyl)piperazine
  参考文献：
  名称：

  Procaspase-activating compounds and compositions

  摘要：

  本发明提供了一种可用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。本发明还提供了合成和使用这些化合物和组合物的方法，包括在治疗癌症和选择性诱导细胞凋亡方面使用这些化合物和组合物的方法。

  公开号：

  US08916705B2

文献信息

• PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS
  申请人：The Board of Trustees of the University of Illinoi

  公开号：US20130096133A1

  公开（公告）日：2013-04-18

  The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

  这项发明提供了用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。该发明还提供了合成和使用这些化合物和组合物的方法，包括在治疗癌症和选择性诱导细胞凋亡中使用这些化合物和组合物的方法。
• Procaspase-activating compounds and compositions
  申请人：The Board of Trustees of the University of Illinois

  公开号：US08916705B2

  公开（公告）日：2014-12-23

  The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

  本发明提供了一种可用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。本发明还提供了合成和使用这些化合物和组合物的方法，包括在治疗癌症和选择性诱导细胞凋亡方面使用这些化合物和组合物的方法。
• Procaspase-activating compounds and methods
  申请人：The Board of Trustees of the University of Illinois

  公开号：US10022371B2

  公开（公告）日：2018-07-17

  The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

  本发明提供了可用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。本发明还提供了合成和使用这些化合物和组合物的方法，包括将化合物和组合物用于治疗癌症和选择性诱导细胞凋亡。
• US8916705B2
  申请人：——

  公开号：US8916705B2

  公开（公告）日：2014-12-23
• Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)
  作者：Danny C. Hsu、Howard S. Roth、Diana C. West、Rachel C. Botham、Chris J. Novotny、Steven C. Schmid、Paul J. Hergenrother

  DOI：10.1021/co2001372

  日期：2012.1.9

  Procaspase-Activating Compound 1 (PAC-1) is an ortho-hydroxy N-acyl hydrazone that enhances the enzymatic activity of procaspase-3 in vitro and induces apoptosis in cancer cells. An analogue of PAC-1, called S-PAC-1, was evaluated in a veterinary clinical trial in pet dogs with lymphoma and found to have considerable potential as an anticancer agent. With the goal of identifying more potent compounds in this promising class of experimental therapeutics, a combinatorial library based on PAC-1 was created, and the compounds were evaluated for their ability to induce death of cancer cells in culture. For library construction, 31 hydrazides were condensed in parallel with 27 aldehydes to create 837 PAC-1 analogues, with an average purity of 91%. The compounds were evaluated for their ability to induce apoptosis in cancer cells, and through this work, six compounds were discovered to be substantially more potent than PAC-1 and S-PAC-1. These six hits were further evaluated for their ability to relieve zinc-mediated inhibition of procaspase-3 in vitro. In general, the newly identified hit compounds are two- to four-fold more potent than PAC-1 and S-PAC-1 in cell culture, and thus have promise as experimental therapeutics for treatment of the many cancers that have elevated expression levels of procaspase-3.